Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen: A Single-Center Retrospective Study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Progression free surviva (PFS)
研究概览
简要总结
A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen
详细描述
Not provided
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women aged 18-
- •The pathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［ER-negative(IHC<1%), PR-negative(IHC<1%), HER2-negative（IHC-/+ or IHC++ and FISH/CISH-）］.
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.
- •Patients receiving eribulin-based therapy received at least two cycles of eribulin-based chemotherapy. Eribulin was treated until disease progression, unacceptable toxicity or patient refusal of treatment.
- •Adverse events were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE 5.0).
排除标准
- •Patients previously treated with eribulin.
- •Patients with grade ≥3 adverse events did not recover according to CTCAE 5.0 criteria.
- •Not applicable to combined chemotherapy, or allergic or intolerant to related drugs.
研究组 & 干预措施
Eribulin-Based Regimen
Not Applicable since observational study
干预措施: Eribulin-Based Regimen (Drug)
Eribulin-Based Regimen
Not Applicable since observational study
干预措施: nab-paclitaxel based regimen (Drug)
Eribulin-Based Regimen
Not Applicable since observational study
干预措施: Other Chemotherapy Regimen (Drug)
nab-paclitaxel based regimen
Not Applicable since observational study
干预措施: Eribulin-Based Regimen (Drug)
nab-paclitaxel based regimen
Not Applicable since observational study
干预措施: nab-paclitaxel based regimen (Drug)
nab-paclitaxel based regimen
Not Applicable since observational study
干预措施: Other Chemotherapy Regimen (Drug)
Other Chemotherapy Regimen
Not Applicable since observational study
干预措施: Eribulin-Based Regimen (Drug)
Other Chemotherapy Regimen
Not Applicable since observational study
干预措施: nab-paclitaxel based regimen (Drug)
Other Chemotherapy Regimen
Not Applicable since observational study
干预措施: Other Chemotherapy Regimen (Drug)
结局指标
主要结局
Progression free surviva (PFS)
时间窗: up to 24 months
The interval from the date of randomization to the first imaging confirmed progression of disease or death from any cause.
Overall survival (OS)
时间窗: up to 24 months
The time interval from the date of randomization to death due to any cause.
次要结局
- Disease Control Rate (DCR)(12 months)
- Overall response rate (ORR)(12 months)
- Incidence of adverse events(12 months)